Corton Capital’s 4D Molecular Therapeutics FDMT Stock Holding History

Corton Capital’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-32,722	Closed	-$182K	–	253
2024 Q4	$182K	Buy	+32,722	New	+$257K	0.1%	284

Other funds holding FDMT

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Corton Capital's FDMT Position: Q1 2025 in Review

Corton Capital sold out of 4D Molecular Therapeutics (FDMT) in Q1 2025, closing a stake of 32,722 shares — an estimated $182K sold.

Corton Capital first reported a position in FDMT in Q4 2024 and held it in 1 quarter. The position peaked at $182K in Q4 2024. 125 funds tracked by Wall St. Rank hold FDMT as of Q1 2025.

Corton Capital reported no remaining 4D Molecular Therapeutics position as of Q1 2025 after selling out during the quarter.
Corton Capital sold 32,722 4D Molecular Therapeutics shares in Q1 2025, an estimated $182K.
Corton Capital first reported a position in 4D Molecular Therapeutics in Q4 2024 and held it in 1 quarter.
Corton Capital's 4D Molecular Therapeutics position peaked at $182K in Q4 2024.
125 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2025.

Based on Corton Capital's 13F filing for Q1 2025, filed 7 May 2025.